Health ❯Clinical Trials

Vaccine Trials

Nipah Vaccine Moderna mRNA Vaccines FDA Approval

FDA Approves Moderna’s Lower-Dose COVID-19 Booster for Seniors and High-Risk Individuals

The CDC has withdrawn routine vaccine recommendations for low-risk populations following federal tightening of booster eligibility rules.

FDA Approves Moderna’s mNEXSPIKE for Seniors and High-Risk Adults as CDC Drops Recommendations for Healthy Children and Pregnant Women

HHS and NIH Launch $500 Million Universal Vaccine Initiative Using Whole-Virus Approach

Norovirus Cases Surge in UK, Doubling Five-Year Average

Kerala Mobilizes to Contain Nipah Virus After Teenager's Death